Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis

Published:2019-06 Issue:3 Volume:32 Page:305-312
ISSN:1350-7540
Container-title:Current Opinion in Neurology
language:en
Short-container-title:

Author:

Schweitzer Finja,Laurent Sarah,Fink Gereon R.,Barnett Michael H.,Reddel Stephen,Hartung Hans-Peter,Warnke Clemens

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Neurology

Reference56 articles.

1. Treatment of multiple sclerosis – success from bench to bedside;Tintore;Nat Rev Neurol,2019

2. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort;Rotstein;JAMA Neurol,2015

3. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial;Wolinsky;Ann Neurol,2018

4. Managing risks with immune therapies in multiple sclerosis;Förster;Drug Saf,2019

5. Infections in patients receiving multiple sclerosis disease-modifying therapies;Grebenciucova;Curr Neurol Neurosci Rep,2017

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

2. Understanding the Complex Dynamics of Immunosenescence in Multiple Sclerosis: From Pathogenesis to Treatment;Biomedicines;2024-08-19

3. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years;Neurology;2024-07-23

4. Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry;Journal of the Neurological Sciences;2024-06

5. Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis;Journal of Personalized Medicine;2024-04-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3